Ulocuplumab (BMS-936564) is a first-in-class fully human IgG4 monoclonal anti-CXCR4 antibody that inhibits the binding of CXCR4 to CXCL12. The CXCR4/CXCL12 (SDF-1) axis has been known for many years as a critical regulator of tumor proliferation, cell, as well as migration into and out of the bone marrow.
Host species | Human |
Isotype | IgG4-kappa |
Species reactivity | Human |
Form | Liquid |
Storage buffer | 0.01M PBS, pH 7.4. |
Purity | >95% as determined by SDS-PAGE. |
Clonality | Monoclonal |
Applications | Research Grade Biosimilar |
Target | Stromal cell-derived factor 1 receptor, LCR1, HM89, LPS-associated protein 3, LAP-3, CXC-R4, CXCR-4, SDF-1 receptor, CD184, NPYRL, LESTR, Fusin, FB22, C-X-C chemokine receptor type 4, CXCR4, Lipopolysaccharide-associated protein 3, Leukocyte-derived seven transmembrane domain receptor |
Purification | Protein A/G purified from cell culture supernatant. |
Endotoxin level | Please contact with the lab for this information. |
Expression system | Mammalian Cells |
Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
Alternative Names | BMS-936564, MDX-1338, MDX1338,CAS: 1375830-34-4 |
Note | For research use only. Not suitable for clinical or therapeutic use. |